Leap Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Thank you. It's a pleasure to start the new year here at the 40th Annual JPMorgan Healthcare Conference. I'm Doug Onsi, the President and CEO of Leap Therapeutics, and I'm proud to be able to give you an update on the clinical development of DKN-01 and our plans for 2022. Then we'll head into the virtual breakout room for questions and answers. While I'll be joined by Cyndi Sirard, our Chief Medical Officer; and Jay Baum, our Vice President and Head of Translational Research. My presentation will include forward-looking statements.
Please advance to Slide 3. LEAP Therapeutics is an oncology drug development company focused on developing our DKN-01 monoclonal antibody. DKN-01 targets DKK1, a protein produced by cancer cells that modulates important cell signaling pathways and playing a key role in maintaining an immunosuppressive tumor microenvironment. DKN-01 has demonstrated single-agent activity in 3 tumor types: esophagogastric cancer, non-small cell lung cancer and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |